HLY78

HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research^[1][2][3]. IC50 & Target: Wnt/β-catenin^[1] In Vitro: HLY78 inhibits apoptosis in tumor cells and embryonic cells caused by carbon ion radiation through activation of the Wnt/β-catenin pathway^[2].
HLY78 (20 μM, 0-48 h) significantly increases the colony formation ability by 2.78-fold and 2.88-fold for HGC-27 and AGS cells compared with the controls^[3].
HLY78 (20 μM, 0-48 h) elevates the migration ability of HGC-27 and AGS cells^[3].
HLY78 significantly increases TNKS expression, which is ameliorated by Dihydroartemisinin (HY-N0176)^[3]. In Vivo: HLY78 (0-1.8 mg/kg, Intranasal injection, once) attenuates neuronal apoptosis and improves neurological deficits through the LRP6/GSK3β/β-catenin signaling pathway after SAH (subarachnoid hemorrhage) in rats^[2].